×

Radiolabelled antibody cytotoxic therapy of infectious or autoimmune disease

  • US 5,609,846 A
  • Filed: 03/27/1995
  • Issued: 03/11/1997
  • Est. Priority Date: 03/29/1988
  • Status: Expired due to Term
First Claim
Patent Images

1. In a method of therapy of an infectious or autoimmune disease, wherein a human patient suffering from an infectious or autoimmune disease susceptible to treatment with a cytotoxic agent is treated with a therapeutic amount of a cytotoxic agent which also produces hematopoietic or myeloid toxicity,the improvement which comprises administering to said patient an amount effective for substantially preventing, mitigating or reversing such hematopoietic or myeloid toxicity, of interleukin-1 (IL-1) alone or in combination with one or more additional differentiation/maturation-inducing cytokines other than interleukin-2, prior to, simultaneously with or subsequent to exposure to said cytotoxic agent;

  • wherein said cytotoxic agent is a radioisotope, drug or toxin conjugated to an antibody or antibody fragment which specifically binds to an antigen which is produced by or associated with an infectious agent or a non-cancerous lymphocyte, provided that said cytotoxic agent is not tumor necrosis factor (TNF).

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×